Price
$7.45-66.89%Social Signal Score
Analyst Ratings
10 analysts52-week range
- Last close
- $7.45
- Off 52w high
- -78.9%
- 200-day average
- $23.19
- vs 200-day
- -67.9%
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Linda Marbán
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 231
- Beta
- 0.53
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.63
Financials
Revenue
$0.00-100.0%Net Income
$-40.73MEBITDA
$255.15MFree Cash Flow
$-37.39MEPS (diluted)
$-0.70Shares Outstanding (diluted)
57.93M+3067.1%Operating Expenses
$42.95MCash & Debt
$237.93MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-105.04M | $-2.26 |
| 2024 | $22.27M | $-40.47M | $-1.15 |
| 2023 | $25.18M | $-22.29M | $-0.83 |
| 2022 | $2.55M | $-29.02M | $-1.18 |
| 2021 | $244.9K | $-20.02M | $-0.87 |
| 2020 | $310.3K | $-13.66M | $-0.88 |
| 2019 | $1.01M | $-7.64M | $-2.06 |
| 2018 | $1.67M | $-15.19M | $-5.17 |
| 2017 | $2.67M | $2.43M | $1.00 |
| 2016 | $3.19M | $-18.81M | $-10.14 |
| 2015 | $3.78M | $-12.86M | $-8.09 |
| 2014 | $4.17M | $-6.22M | $-5.31 |
| 2013 | $503.2K | $-8.89M | $-8.47 |
| 2012 | $195.5K | $-1.89M | $-2.10 |
Valuation
CAPRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
0-100.00%Social Signal Score
Mentions (21)
- Newsglobenewswire.com·13d ago·Negative
$CAPR Stock Notification: Capricor Therapeutics has been Sued for Securities Fraud after Clinical Data Issues Disclosed – Investors are Alerted to Contact BFA Law by September 28 Capricor Therapeutics has been Sued for Securities Fraud after Clinical Data Issues Disclosed – Investors are Alerted to Contact BFA Law by September 28
View source ↗ - Newsgurufocus.com·14d ago·Negative
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Sept. 22, 2026LOS ANGELES, Sept
View source ↗ - Newsprnewswire.com·18d ago·Negative
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM, Pa., Sept. 17, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newsmarketbeat.com·22d ago·Neutral
3 Small-Cap Biotechs With Binary Catalysts on the Calendar For small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting everything on a single clinical trial readout or an FDA decision.
View source ↗ - Newsprnewswire.com·28d ago·Negative
CAPR Lawsuit Alert: Capricor Therapeutics Investors Face September 28 Deadline After 64% Stock Drop Tied to Clinical Data Disclosure Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop. NEW YORK, Sept.
View source ↗ - Newszacks.com·28d ago·Positive
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.
View source ↗ - Newsprnewswire.com·33d ago·Negative
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Sept. 2, 2026 /PRNewswire/ -- The Law Offices of Frank R.
View source ↗ - Newsgurufocus.com·35d ago·Negative
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK,
View source ↗ - Newsbenzinga.com·42d ago·Neutral
Why Is Capricor Therapeutics Stock Trading Higher on Monday? Capricor Therapeutics Inc (NASDAQ:CAPR) stock is trading higher on Monday as investors react to the FDA's continued review of deramiocel update.
View source ↗ - Newsreuters.com·42d ago·Negative
US FDA extends review of Capricor's muscle disorder therapy by three months Capricor Therapeutics said on Monday that the U.S. Food and Drug Administration had extended the review of its experimental cell therapy for Duchenne muscular dystrophy by three months.
View source ↗ - Newsprnewswire.com·46d ago·Positive
Kaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholders /PRNewswire/ -- Kaos Capital Ltd. ("Kaos Capital," "we," or "us"), a significant and growing shareholder of Capricor Therapeutics, Inc. (NASDAQ: CAPR)
View source ↗ - Newsnewsfilecorp.com·52d ago·Neutral
…and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.
View source ↗ - Newsglobenewswire.com·52d ago·Positive
CAPR Stockholders Have Rights – If You Lost Money Investing in Capricor Therapeutics, Inc. Contact Robbins LLP for Information About Leading the Class Action Robbins LLP is Investigating Allegations That Capricor Therapeutics, Inc. Misled Investors Regarding the Facts About the Path to FDA Approval for Deramioce
View source ↗ - Newsseekingalpha.com·52d ago·Neutral
…estors Must Know Capricor Therapeutics, Inc. surged 75% after announcing ongoing FDA negotiations for deramiocel, in Duchenne Muscular Dystrophy with cardiomyopathy. CAPR plans to amend its BLA with 24-month HOPE-3 extension data, following positive Lancet publication and FDA willingness to review the new submission. Despite prior AdCom rejection and protocol reporting issues, HOPE-3's primary endpoint may be statistically and clinically significant, supporting potential regulatory reconsiderati…
View source ↗ - Newsbenzinga.com·53d ago·Neutral
Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading higher on Friday after the gene therapy company released second-quarter earnings on Thursday after market close.
View source ↗ - Newsreuters.com·53d ago·Neutral
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data Capricor Therapeutics shares more than doubled in premarket trading on Friday after the company said the U.S. health regulator is willing to review new data on its experimental Duchenne muscular dystrophy drug.
View source ↗ - Newsseekingalpha.com·53d ago·Neutral
Capricor Therapeutics, Inc. (CAPR) Q2 2026 Earnings Call Prepared Remarks Transcript Capricor Therapeutics, Inc. (CAPR) Q2 2026 Earnings Call Prepared Remarks Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Negative
Capricor Therapeutics Q2 Earnings Call Highlights Capricor Therapeutics NASDAQ: CAPR said its biologics license application for deramiocel remains under U.S. Food and Drug Administration review, while the company prepares to submit an amendment seeking a refined indication centered on upper limb skeletal muscle function in Duchenne muscular dystrophy, or DMD.
View source ↗ - Newsnewsfilecorp.com·53d ago·Neutral
…and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.
View source ↗ - Newsglobenewswire.com·57d ago·Neutral
Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13 – Company to Host Conference Call on August 13, 2026, at 4:30 p.m. ET – – Company to Host Conference Call on August 13, 2026, at 4:30 p.m. ET –
View source ↗ - Newsgurufocus.com·57d ago·Negative
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law PR Newswire
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.14 per share
Typical surprise -18.7% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.70 vs $-0.59miss
- Tue, May 12$-0.59 vs $-0.55miss
- Thu, Mar 12$-0.62 vs $-0.51miss
- Mon, Nov 10$-0.54 vs $-0.54beat
- Mon, Aug 11$-0.57 vs $-0.48miss
- Tue, May 13$-0.53 vs $-0.33miss
Estimates and results for CAPR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CAPR officers and directors.
- Bought
- —
- Sold
- $8.3m
0 trades
11 trades
- Krasney Karensold
- Bergmann Anthonysold
- Krasney Karensold
- Bergmann Anthonysold
- Krasney Karensold
- Bergmann Anthonysold
- Sabar Karimah Essold
- Sabar Karimah Essold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Roger Wayne Marshallhouse · KS01 · disclosed Aug 6, 2018 (375d later)Buy$1,001 - $15,000
- Roger Wayne Marshallhouse · KS01 · disclosed Aug 6, 2018 (375d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.